Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Waste Management

JanOne, Inc. focuses on finding treatments for conditions that cause severe pain and markets drugs with non-addictive pain-relieving properties. The company is headquartered in Las Vegas, Nevada and currently employs 154 full-time employees. The firm has two segments: recycling and retail. The company sells household appliances in the United States though its chain of Company-owned retail stores, operating under the name ApplianceSmart. Its recycling segment focuses on collecting, recycling and installing appliances for utilities and other customers. Its recycling segment focuses on the agreement with General Electric (GE). Its retail segment focuses on the sale of appliances through ApplianceSmart stores. The company is a household appliance retailer with product categories, including commonly available appliances, and offerings, such as close-outs, factory overruns, discontinued models and special-buy appliances, including out-of-carton merchandise and others. The company offers extended warranties, factory-trained technician service and recycling of customers` replaced appliances.
Website: janone.com



Growth: Bad revenue growth rate -25.0%, there is slowdown compared to average historical growth rates 24.4%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -7.5%. On average the margin is decreasing steadily. Gross margin is low, +12.0%.

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -76.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 1 600.0% higher than minimum and 45.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.6x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: JAN
Share price, USD:  (+8.3%)5.1
year average price 1.05  


year start price 0.93 2023-04-29

min close price 0.30 2023-11-07

max close price 5.10 2024-04-26

current price 5.10 2024-04-27
Common stocks: 2 827 410

Dividend Yield:  0.0%
Last revenue growth (y/y):  -25.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  24.4%
Historical growth of EBITDA:  ---
EV / Sales: 0.6x
Margin (EBITDA LTM / Revenue): -7.5%
Fundamental value created in LTM:
Market Cap ($m): 14
Net Debt ($m): 9
EV (Enterprise Value): 23
Price to Book: 1.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-09-21PRNewsWire

JanOne to Present at the Dawson James 8th Annual Investment Conference

2023-08-31PRNewsWire

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

2023-08-18PRNewsWire

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-10-01 2022-07-02
symbol JAN JAN JAN JAN JAN JAN JAN
reportedCurrency USD USD USD USD USD USD USD
cik 862 861 862 861 862 861 862 861 862 861 862 861 862 861
fillingDate 2024-04-08 2023-09-30 2023-08-15 2023-05-22 2023-04-17 2022-11-14 2022-08-15
acceptedDate 2024-04-08 16:21:09 2023-09-29 20:00:00 2023-08-15 16:39:17 2023-05-22 16:31:23 2023-04-17 16:50:53 2022-11-14 17:01:00 2022-08-15 18:10:48
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 0 11M 9M 11M
costOfRevenue 400 000 363 000 363 000 0 8M 8M 9M
grossProfit -400 000 -363 000 -363 000 0 3M 1M 2M
grossProfitRatio 0 0 0 0 0.276 0.120 0.156
researchAndDevelopmentExpenses 0 0 0 0 0 0 0
generalAndAdministrativeExpenses 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 1M 764 000 1M 1M 3M 3M 3M
otherExpenses 253 000 6000.000 757 000 -18 000 908 000 0 0
operatingExpenses 1M 764 000 1M 1M 3M 3M 3M
costAndExpenses 2M 764 000 1M 1M 11M 10M 12M
interestIncome 652 000 758 000 365 000 0 0 0 0
interestExpense 0 0 365 000 475 000 9M 36 000 -98 000
depreciationAndAmortization 400 000 363 000 363 000 611 000 265 000 347 000 -102 000
ebitda -1M -134 000 -697 000 -488 000 3M -1M 11M
ebitdaratio 0 0 0 0 0.301 -0.172 1.018
operatingIncome -2M -764 000 -1M -1M 3M -2M 11M
operatingIncomeRatio 0 0 0 0 0.277 -0.212 1.028
totalOtherIncomeExpensesNet -15M -261 000 757 000 210 000 -16M -234 000 -141 000
incomeBeforeTax -16M -267 000 62 000 -889 000 -13M -2M 11M
incomeBeforeTaxRatio 0 0 0 0 -1.158 -0.240 1.015
incomeTaxExpense -160 000 -25 000 -17 000 -227 000 -7M 16 000 4000.000
netIncome -14M -214 000 123 000 -662 000 -6M -2M 11M
netIncomeRatio 0 0 0 0 -0.559 -0.242 1.014
eps -2.870 -0.051 0.034 -0.210 -1.980 -0.660 3.390
epsdiluted -2.870 -0.051 0.034 -0.210 -1.980 -0.660 3.060
weightedAverageShsOut 5M 4M 4M 3M 3M 3M 3M
weightedAverageShsOutDil 5M 4M 4M 3M 3M 3M 3M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-10-01 2022-07-02
symbol JAN JAN JAN JAN JAN JAN JAN
reportedCurrency USD USD USD USD USD USD USD
cik 862 861 862 861 862 861 862 861 862 861 862 861 862 861
fillingDate 2024-04-08 2023-09-30 2023-08-15 2023-05-22 2023-04-17 2022-11-14 2022-08-15
acceptedDate 2024-04-08 16:21:09 2023-09-29 20:00:00 2023-08-15 16:39:17 2023-05-22 16:31:23 2023-04-17 16:50:53 2022-11-14 17:01:00 2022-08-15 18:10:48
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 5000.000 413 000 169 000 353 000 115 000 868 000 1M
shortTermInvestments 0 0 0 0 0 0 0
cashAndShortTermInvestments 5000.000 413 000 169 000 353 000 115 000 868 000 1M
netReceivables 266 000 19 000 15 000 15 000 8M 7M 4M
inventory 0 0 0 0 366 000 415 000 494 000
otherCurrentAssets 75 000 85 000 102 000 269 000 770 000 1M 869 000
totalCurrentAssets 346 000 517 000 286 000 637 000 9M 9M 7M
propertyPlantEquipmentNet 0 0 12M 0 8M 8M 7M
goodwill 0 0 0 0 0 0 0
intangibleAssets 18M 18M 19M 19M 20M 328 000 345 000
goodwillAndIntangibleAssets 18M 18M 19M 19M 20M 328 000 345 000
longTermInvestments 286 000 222 000 237 000 162 000 315 000 300 000 570 000
taxAssets 0 0 3M 3M 0 0 0
otherNonCurrentAssets 9000.000 16M 17 000 12M 9M 13M 13M
totalNonCurrentAssets 18M 34M 34M 34M 38M 22M 21M
otherAssets 0 0 0 0 0 0 0
totalAssets 18M 34M 34M 35M 47M 31M 28M
accountPayables 2M 2M 2M 3M 7M 6M 6M
shortTermDebt 0 0 0 69 000 7M 6M 2M
taxPayables 102 000 146 000 99 000 47 000 6M 7M 7M
deferredRevenue 0 0 0 0 290 000 678 000 331 000
otherCurrentLiabilities 4M 243 000 495 000 744 000 10M 11M 11M
totalCurrentLiabilities 6M 3M 3M 3M 24M 24M 19M
longTermDebt 707 000 0 0 0 6M 6M 5M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 639 000 3M 3M 3M 195 000 0 0
otherNonCurrentLiabilities 34 000 15M 15M 15M 46 000 -6M -3M
totalNonCurrentLiabilities 1M 17M 18M 18M 6M 6M 5M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 5M 6M 4M
totalLiabilities 7M 20M 21M 21M 30M 30M 24M
preferredStock 15M 15M 15M 15M 0 0 0
commonStock 3000.000 3000.000 3000.000 3000.000 2000.000 3000.000 2000.000
retainedEarnings -51M -33M -33M -33M -43M -44M -42M
accumulatedOtherComprehensiveIncomeLoss -3000.000 -15M -15M 0 -621 000 -617 000 -617 000
othertotalStockholdersEquity 47M 47M 46M 32M 60M 46M 46M
totalStockholdersEquity 11M 14M 14M 14M 17M 1M 3M
totalEquity 11M 14M 14M 14M 17M 1M 3M
totalLiabilitiesAndStockholdersEquity 18M 34M 34M 35M 47M 31M 28M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 18M 34M 34M 35M 47M 31M 28M
totalInvestments 286 000 222 000 237 000 162 000 315 000 300 000 570 000
totalDebt 707 000 0 0 69 000 12M 12M 7M
netDebt 702 000 -413 000 -169 000 -284 000 12M 11M 6M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-10-01 2022-07-02
symbol JAN JAN JAN JAN JAN JAN JAN
reportedCurrency USD USD USD USD USD USD USD
cik 862 861 862 861 862 861 862 861 862 861 862 861 862 861
fillingDate 2024-04-08 2023-09-30 2023-08-15 2023-05-22 2023-04-17 2022-11-14 2022-08-15
acceptedDate 2024-04-08 16:21:09 2023-09-29 20:00:00 2023-08-15 16:39:17 2023-05-22 16:31:23 2023-04-17 16:50:53 2022-11-14 17:01:00 2022-08-15 18:10:48
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -16M -242 000 79 000 -662 000 1M -2M 11M
depreciationAndAmortization 400 000 363 000 363 000 364 000 265 000 77 000 137 000
deferredIncomeTax 444 000 267 000 0 0 0 0 0
stockBasedCompensation 0 2000.000 4000.000 8000.000 1000.000 0 0
changeInWorkingCapital -871 000 -326 000 -273 000 379 000 -1M -2M 348 000
accountsReceivables -873 000 164 000 345 000 -3000.000 -1M -3M 557 000
inventory 0 160 000 785 000 0 49 000 79 000 650 000
accountsPayables -363 000 -160 000 -785 000 256 000 0 0 0
otherWorkingCapital 365 000 -490 000 -618 000 -253 000 28 000 394 000 -859 000
otherNonCashItems 18M -503 000 -288 000 2M -1M 205 000 -12M
netCashProvidedByOperatingActivities -409 000 -439 000 -115 000 2M -665 000 -4M -566 000
investmentsInPropertyPlantAndEquipment 0 0 0 0 -559 000 -40 000 -783 000
acquisitionsNet 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0
otherInvestingActivites 1000.000 0 0 -156 000 0 0 -189 000
netCashUsedForInvestingActivites 1000.000 0 0 -156 000 -559 000 -40 000 -783 000
debtRepayment 0 0 -69 000 -205 000 -12M -727 000 -190 000
commonStockIssued 0 424 000 0 368 000 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 0 259 000 -69 000 -2M 13M 4M 366 000
netCashUsedProvidedByFinancingActivities 0 683 000 -69 000 -2M 475 000 4M 176 000
effectOfForexChangesOnCash 0 0 0 17 000 -4000.000 0 41 000
netChangeInCash -408 000 244 000 -184 000 238 000 -753 000 -313 000 -1M
cashAtEndOfPeriod 5000.000 413 000 169 000 353 000 115 000 868 000 1M
cashAtBeginningOfPeriod 413 000 169 000 353 000 115 000 868 000 1M 2M
operatingCashFlow -409 000 -439 000 -115 000 2M -665 000 -4M -566 000
capitalExpenditure 0 0 0 0 -559 000 -40 000 -783 000
freeCashFlow -409 000 -439 000 -115 000 2M -1M -4M -1M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-03-15 13:00 ET
JanOne Regains Compliance with Nasdaq's Listing Requirements
2023-09-21 15:30 ET
JanOne to Present at the Dawson James 8th Annual Investment Conference
2023-08-31 17:30 ET
JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference
2023-08-29 17:30 ET
JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain
2023-08-25 18:30 ET
JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting
2023-08-18 23:00 ET
JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules
2023-08-18 16:42 ET
JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting
2023-06-28 12:30 ET
JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain
2023-04-18 12:30 ET
JanOne Completes Pre-IND Meeting with FDA on Jan123
2023-04-13 12:30 ET
JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023
2023-03-23 12:30 ET
JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team
2023-03-23 12:00 ET
JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market
2023-03-22 12:30 ET
JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses
2023-02-22 13:30 ET
JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians
2023-01-26 13:30 ET
JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management
2023-01-10 13:30 ET
JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC
2022-09-16 13:30 ET
JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC
2022-07-05 13:00 ET
ARCA Recycling, a Subsidiary of JanOne Inc., Unveils New Logo and Website
2022-06-28 13:00 ET
JanOne Inc. Announces an Improved Formulation of JAN101
2022-06-09 12:30 ET
ARCA Recycling, Inc., a Subsidiary of JanOne Inc., Opens Three New Recycling Centers in Washington, California and New Jersey
2022-06-07 12:30 ET
JanOne Inc. Announces the Issuance of U.S. Patent Covering a Method of Improving Nerve Function Using JAN101
2022-05-31 12:30 ET
JanOne Sells GeoTraq to SPYR Technologies in a $13.5 Million Transaction
2022-01-04 14:00 ET
JanOne Inc. Develops Plan for Treating Methamphetamine Use Disorder
2021-12-16 14:00 ET
ARCA Recycling, a Subsidiary of JanOne Inc., Awarded Recycling Contract in Virginia and North Carolina With Total Estimated Value of $1.6 Million for Work through 2023
2021-12-07 14:00 ET
JanOne Inc. Acquires an Option for the Rights to a Worldwide, Exclusive License for a Novel Strategy for Treating Methamphetamine Use Disorder
2021-10-27 13:00 ET
ARCA Recycling, a Subsidiary of JanOne Inc., Launches Two Recycling Programs in California in Effort to Reduce GHG Emissions
2021-10-19 13:00 ET
ARCA Recycling, a Subsidiary of JanOne Inc., Sees Major Increase in Appliance Replacement Contracts, Estimated to Push Revenue of Replacement Programs to Nearly $20 Million, in Addition to Recycling Business
2021-10-12 13:00 ET
ARCA Recycling, a Subsidiary of JanOne Inc., Opens Recycling Center in Michigan to Support New Multi-Year Contracts Totaling Millions in Revenue
2021-10-07 13:00 ET
ARCA Recycling, a Subsidiary of JanOne Inc., Awarded Recycling Contracts in Pennsylvania With Total Estimated Value of 20 Million Dollars for Work in the State to Continue Through 2026
2021-09-30 13:00 ET
ARCA Recycling, a Subsidiary of JanOne Inc., Opens New Pennsauken, NJ, Recycling Center, Launches New Recycling Programs
2021-09-28 20:05 ET
JanOne Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate JAN101
2021-07-22 13:45 ET
JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients
2021-06-23 14:10 ET
JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites
2021-06-22 13:46 ET
JanOne Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing
2021-06-15 14:15 ET
JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board
2021-06-10 14:15 ET
JanOne Engages DC Consulting LLC for Government and Private Sector Initiatives
2021-06-08 13:45 ET
JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101
2021-02-25 14:29 ET
JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million
2021-02-02 16:45 ET
JanOne Announces Closing of $6.0 Million Common Stock Offering
2021-01-29 13:45 ET
JanOne Prices $6.0 Million Common Stock Offering
2020-09-24 14:45 ET
JanOne Successfully Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study
2020-09-22 13:45 ET
JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease
2020-09-16 18:37 ET
JanOne Announces Strategic Plan to Divest its Legacy Businesses
2020-09-03 14:30 ET
JanOne confirms stability data of JAN101 development batch and prepares for commercial GMP production to support the upcoming PAD and potential Covid-19 clinical trials
2020-08-28 18:34 ET
JanOne Selects Partner for Bottling and Labeling of JAN101 for Peripheral Artery Disease and Potential Covid-19 Clinical Trials
2020-08-26 13:45 ET
JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness
2020-08-21 14:31 ET
JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular Complications
2020-08-19 18:50 ET
JanOne to Present at The LD 500 Virtual Conference
2020-08-11 13:37 ET
/C O R R E C T I O N -- JanOne/
2020-08-06 18:30 ET
JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications
2020-08-04 13:47 ET
JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101
2020-07-30 13:30 ET
JanOne bolsters its scientific advisory board with two leaders in the medical field for vascular regeneration and interventional pain
2020-07-21 13:25 ET
JanOne Receives FDA Authorization for Transfer of Investigational New Drug (IND) Application for its Sodium Nitrite Tablets
2020-07-08 13:30 ET
Dr. Rakesh Patel, internationally recognized scientist in nitric oxide and redox biology, and Dr. Timothy Ness, a pain mechanisms and medication expert, join JanOne's Scientific Advisory Board
2020-06-30 13:30 ET
One of the nation's most renowned pain experts, Dr. Edgar Ross, joins JanOne's Scientific Advisory Board
2020-06-25 18:23 ET
JanOne taps distinguished chemist Dr. Doug Flanagan as chief formulation advisor
2020-06-18 13:27 ET
JanOne Launches Strategic Alternatives Process for Legacy Businesses
2020-02-06 14:02 ET
JanOne strikes agreement with CoreRx, a leading cGMP contract manufacturer, for Phase 2b clinical formulation and development
2020-01-28 14:02 ET
Amol Soin, MD, One Of The Nation's Leading Pain Experts, Named As JanOne's Chief Medical Officer
2020-01-23 14:02 ET
JanOne Scientific Advisory Board Chair and Leading Pain Expert Featured on ABC-7 WJLA America This Week
2020-01-16 15:51 ET
Leading Cardiovascular Researcher And PAD Treatment Pioneer, Dr. Christopher Kevil, To Chair JanOne Scientific Advisory Board
2019-12-03 14:03 ET
JanOne Names Tony Giordano, Ph.D., as Chief Scientific Officer
2019-11-25 14:00 ET
JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD)
2019-09-05 12:00 ET
Appliance Recycling Centers of America Inc. Announces Major Strategic Shift, Repositioning and Name Change
2019-08-29 12:00 ET
ARCA Announces Significant Increase in Orders in its Recycling Division
2019-08-27 12:00 ET
GeoTraq Named "Top 10 Remote Monitoring Solution Providers - 2019"
2019-07-25 12:00 ET
CIO Bulletin Announces GeoTraq As One of the 30 Most Innovative Companies 2019
2019-06-25 12:00 ET
GeoTraq Raises the Standard for Mobile IoT by Joining GSMA
2019-04-25 12:00 ET
GeoTraq Announces New Class of Mobile IoT Modules
2019-04-18 17:00 ET
Appliance Recycling Centers of America Announces Reverse Stock Split of Common Stock

SEC forms

Show financial reports only

SEC form 10
2024-04-08 16:21 ET
JanOne published news for 2023 q4
SEC form 10
2024-04-08 00:00 ET
JanOne published news for 2023 q4
SEC form 10
2023-11-14 16:26 ET
JanOne reported for 2023 q3
SEC form 10
2023-11-14 00:00 ET
JanOne reported for 2023 q3
SEC form 6
2023-08-28 17:20 ET
JanOne published news for 2023 q2
SEC form 6
2023-08-23 16:33 ET
JanOne published news for 2023 q2
SEC form 6
2023-08-16 15:55 ET
JanOne published news for 2023 q2
SEC form 10
2023-08-15 16:39 ET
JanOne reported for 2023 q2
SEC form 10
2023-08-15 00:00 ET
JanOne reported for 2023 q2
SEC form 6
2023-07-07 16:19 ET
JanOne published news for 2023 q2
SEC form 6
2023-06-30 16:24 ET
JanOne published news for 2023 q1
SEC form 10
2023-05-22 16:31 ET
JanOne reported for 2023 q1
SEC form 10
2023-05-22 00:00 ET
JanOne reported for 2023 q1
SEC form 6
2023-05-11 16:30 ET
JanOne published news for 2023 q1
SEC form 6
2023-04-25 17:03 ET
JanOne published news for 2023 q1
SEC form 6
2023-04-25 17:01 ET
JanOne published news for 2023 q1
SEC form 6
2023-04-21 16:30 ET
JanOne published news for 2023 q1
SEC form 10
2023-04-17 16:50 ET
JanOne reported for 2022 q4
SEC form 10
2023-04-17 00:00 ET
JanOne reported for 2022 q4
SEC form 6
2023-03-24 16:31 ET
JanOne published news for 2022 q4
SEC form 6
2023-03-24 16:30 ET
JanOne published news for 2022 q4
SEC form 6
2023-03-21 17:15 ET
JanOne published news for 2022 q4
SEC form 6
2023-03-20 06:45 ET
JanOne published news for 2022 q4
SEC form 6
2023-03-17 17:56 ET
JanOne published news for 2022 q4
SEC form 6
2023-03-15 17:25 ET
JanOne published news for 2022 q4
SEC form 6
2023-02-13 16:31 ET
JanOne published news for 2022 q4
SEC form 6
2023-01-31 16:30 ET
JanOne published news for 2022 q4
SEC form 6
2023-01-04 16:31 ET
JanOne published news for 2022 q4
SEC form 6
2022-11-25 14:01 ET
JanOne published news for 2022 q3
SEC form 10
2022-11-14 17:01 ET
JanOne reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
JanOne reported for 2022 q3
SEC form 6
2022-11-03 16:31 ET
JanOne published news for 2022 q3
SEC form 6
2022-10-06 16:31 ET
JanOne published news for 2022 q3
SEC form 6
2022-09-30 17:00 ET
JanOne published news for 2022 q2
SEC form 10
2022-08-15 18:10 ET
JanOne reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
JanOne reported for 2022 q2
SEC form 6
2022-06-28 08:30 ET
JanOne published news for 2022 q1
SEC form 6
2022-05-31 08:52 ET
JanOne published news for 2022 q1
SEC form 10
2022-05-12 16:33 ET
JanOne reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
JanOne reported for 2022 q1
SEC form 6
2022-04-15 17:17 ET
JanOne published news for 2022 q1
SEC form 10
2022-04-01 16:31 ET
JanOne published news for 2021 q4
SEC form 10
2022-04-01 00:00 ET
JanOne published news for 2021 q4
SEC form 10
2021-11-15 16:34 ET
JanOne published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
JanOne published news for 2021 q3
SEC form 6
2021-11-05 16:33 ET
JanOne published news for 2021 q3
SEC form 6
2021-10-06 08:30 ET
JanOne published news for 2021 q3
SEC form 6
2021-10-05 16:30 ET
JanOne published news for 2021 q3
SEC form 10
2021-08-16 00:00 ET
JanOne published news for 2021 q2
SEC form 10
2021-08-13 18:55 ET
JanOne published news for 2021 q2
SEC form 6
2021-08-06 17:02 ET
JanOne published news for 2021 q2
SEC form 6
2021-07-22 09:46 ET
JanOne published news for 2021 q2
SEC form 6
2021-06-23 10:14 ET
JanOne published news for 2021 q1
SEC form 6
2021-06-22 09:46 ET
JanOne published news for 2021 q1
SEC form 6
2021-06-15 10:16 ET
JanOne published news for 2021 q1
SEC form 6
2021-06-08 09:45 ET
JanOne published news for 2021 q1
SEC form 10
2021-05-17 17:01 ET
JanOne published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
JanOne published news for 2021 q1
SEC form 6
2021-04-16 17:00 ET
JanOne published news for 2021 q1
SEC form 10
2021-03-30 17:01 ET
JanOne published news for 2020 q4
SEC form 6
2021-02-25 16:05 ET
JanOne published news for 2020 q4
SEC form 6
2021-02-02 17:27 ET
JanOne published news for 2020 q4
SEC form 6
2021-01-29 09:08 ET
JanOne published news for 2020 q4
SEC form 10
2020-11-09 20:01 ET
JanOne published news for 2020 q3
SEC form 6
2020-10-02 16:05 ET
JanOne published news for 2020 q3
SEC form 6
2020-10-01 19:12 ET
JanOne published news for 2020 q3
SEC form 6
2020-09-03 16:05 ET
JanOne published news for 2020 q2